Shanghai - Delayed Quote CNY
Harbin Pharmaceutical Group Co., Ltd. (600664.SS)
3.7800
+0.0400
+(1.07%)
At close: May 23 at 3:00:03 PM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
16,208,119.3096
16,175,856.2392
15,456,578.1044
13,808,761.3278
12,802,015.5533
Cost of Revenue
11,703,276.2895
11,607,227.7442
11,404,770.4760
10,402,693.2618
9,766,068.2155
Gross Profit
4,504,843.0201
4,568,628.4950
4,051,807.6284
3,406,068.0659
3,035,947.3378
Operating Expense
3,494,164.9942
3,594,153.2617
3,291,556.3046
2,746,072.9971
2,444,477.3171
Operating Income
1,010,678.0259
974,475.2334
760,251.3238
659,995.0688
591,470.0207
Net Non Operating Interest Income Expense
-35,549.6759
-31,365.3514
-22,347.7716
-70,610.8133
-97,068.5578
Pretax Income
901,603.5358
875,006.1058
650,539.8232
701,154.1830
630,534.3365
Tax Provision
182,577.0391
184,398.2742
176,321.6503
188,941.8570
220,688.7051
Net Income Common Stockholders
665,034.5728
628,846.5983
395,263.4369
465,150.3006
371,083.7463
Basic EPS
0.26
0.25
0.16
0.19
0.15
Diluted EPS
0.26
0.25
0.16
0.18
0.15
Basic Average Shares
2,549,571.4090
2,515,386.3930
2,470,396.4810
2,448,159.4770
2,473,891.6420
Diluted Average Shares
2,549,571.4090
2,515,386.3930
2,470,396.4810
2,584,168.3370
2,473,891.6420
Total Operating Income as Reported
917,127.8742
890,204.9154
659,629.4498
695,803.2444
642,413.0135
Rent Expense Supplemental
--
9,779.1880
12,321.1851
10,368.2923
13,144.4709
Total Expenses
15,197,441.2837
15,201,381.0059
14,696,326.7806
13,148,766.2589
12,210,545.5326
Net Income from Continuing & Discontinued Operation
665,034.5728
628,846.5983
395,263.4369
465,150.3006
371,083.7463
Normalized Income
716,678.7032
675,935.6451
451,677.8018
419,059.4026
276,724.6084
Interest Income
30,147.0644
37,028.9584
47,096.7525
28,865.8891
15,649.9700
Interest Expense
56,877.3119
60,067.6028
56,468.3496
85,534.8465
105,155.0925
Net Interest Income
-35,549.6759
-31,365.3514
-22,347.7716
-70,610.8133
-97,068.5578
EBIT
958,480.8477
935,073.7086
707,008.1727
786,689.0295
735,689.4290
EBITDA
958,480.8477
1,223,302.4216
1,011,204.7513
1,097,083.6286
1,043,234.0996
Reconciled Cost of Revenue
11,703,276.2895
11,607,227.7442
11,404,770.4760
10,402,693.2618
9,766,068.2155
Reconciled Depreciation
--
288,228.7130
304,196.5786
310,394.5991
307,544.6706
Net Income from Continuing Operation Net Minority Interest
665,034.5728
628,846.5983
395,263.4369
465,150.3006
371,083.7463
Total Unusual Items Excluding Goodwill
-64,757.7395
-59,662.2302
-77,390.0982
63,092.6361
145,168.5020
Total Unusual Items
-64,757.7395
-59,662.2302
-77,390.0982
63,092.6361
145,168.5020
Normalized EBITDA
1,023,238.5871
1,282,964.6519
1,088,594.8496
1,033,990.9925
898,065.5976
Tax Rate for Calcs
0.0002
0.0002
0.0003
0.0003
0.0004
Tax Effect of Unusual Items
-13,113.6091
-12,573.1835
-20,975.7333
17,001.7382
50,809.3642
12/31/2021 - 6/29/1993
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade